IL143528A0 - Therapeutic agents containing botulinum toxin for the suppression of snoring noises - Google Patents

Therapeutic agents containing botulinum toxin for the suppression of snoring noises

Info

Publication number
IL143528A0
IL143528A0 IL14352899A IL14352899A IL143528A0 IL 143528 A0 IL143528 A0 IL 143528A0 IL 14352899 A IL14352899 A IL 14352899A IL 14352899 A IL14352899 A IL 14352899A IL 143528 A0 IL143528 A0 IL 143528A0
Authority
IL
Israel
Prior art keywords
bont
clostridium toxin
carrier
added
suppression
Prior art date
Application number
IL14352899A
Other languages
English (en)
Original Assignee
Biotecon Ges Fur Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fur Biotechnologi filed Critical Biotecon Ges Fur Biotechnologi
Publication of IL143528A0 publication Critical patent/IL143528A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
IL14352899A 1998-12-10 1999-12-10 Therapeutic agents containing botulinum toxin for the suppression of snoring noises IL143528A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (de) 1998-12-10 1998-12-10 Therapeutikum zur Unterdrückung von Schnarchgeräuschen
PCT/EP1999/009791 WO2000033863A2 (fr) 1998-12-10 1999-12-10 Medicament anti-ronflements

Publications (1)

Publication Number Publication Date
IL143528A0 true IL143528A0 (en) 2002-04-21

Family

ID=7890562

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14352899A IL143528A0 (en) 1998-12-10 1999-12-10 Therapeutic agents containing botulinum toxin for the suppression of snoring noises
IL143528A IL143528A (en) 1998-12-10 2001-06-03 Drugs that contain botulinum toxin to reduce snoring noise

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143528A IL143528A (en) 1998-12-10 2001-06-03 Drugs that contain botulinum toxin to reduce snoring noise

Country Status (21)

Country Link
US (1) US6573241B1 (fr)
EP (1) EP1137430B1 (fr)
JP (1) JP4700811B2 (fr)
KR (1) KR100859556B1 (fr)
CN (1) CN1186095C (fr)
AT (1) ATE234108T1 (fr)
AU (1) AU764744B2 (fr)
BR (1) BR9915800A (fr)
CA (1) CA2353469A1 (fr)
CZ (1) CZ295769B6 (fr)
DE (2) DE19856897A1 (fr)
DK (1) DK1137430T3 (fr)
ES (1) ES2192880T3 (fr)
HK (1) HK1040636B (fr)
HU (1) HUP0104702A3 (fr)
IL (2) IL143528A0 (fr)
NO (1) NO328762B1 (fr)
PL (1) PL202908B1 (fr)
PT (1) PT1137430E (fr)
RU (1) RU2243783C2 (fr)
WO (1) WO2000033863A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
EP1898947A2 (fr) * 2005-06-14 2008-03-19 Botulinum Toxin Research Associates, Inc. Toxine botulinique et traitement de troubles primaires de l'humeur et de l'affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
JP5368793B2 (ja) 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル ナノエマルジョンを製造および使用するための組成物および方法
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
TR201901443T4 (tr) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemülsiyonları.
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
BRPI0719732A2 (pt) 2006-12-01 2017-05-16 Anterios Inc nanopartículas de peptídeo e usos para as mesmas
EP2494958A1 (fr) * 2006-12-01 2012-09-05 Anterios, Inc. Nanoparticules d'entité amphiphile
ES2660906T3 (es) 2007-05-31 2018-03-26 Anterios, Inc. Nanopartículas de ácido nucleico y usos de las mismas
WO2009158687A1 (fr) * 2008-06-26 2009-12-30 Anterios, Inc. Administration dermique
WO2010096134A1 (fr) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Formulation de toxine botulique à durée de vie prolongée pour utilisation chez un humain ou un mammifère
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
JP2013510193A (ja) * 2009-11-09 2013-03-21 サンダース，イラ 神経毒を用いる睡眠呼吸障害の処置
PL2677029T3 (pl) 2011-05-19 2017-10-31 Ipsen Bioinnovation Ltd Sposoby wytwarzania poddanych obróbce proteolitycznej polipeptydów
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
JP6156954B2 (ja) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド タンパク分解性にプロセシングされたポリペプチドの製造方法
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
WO1994000481A1 (fr) * 1992-06-23 1994-01-06 Associated Synapse Biologics Composition pharmaceutique contenant un complexe de botulinum b
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
AU688452B2 (en) * 1993-12-28 1998-03-12 Allergan, Inc. Botulinum toxins for treating various disorders and associated pain
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9310728B2 (en) 2013-06-13 2016-04-12 Lexmark International, Inc. Latch mechanism for a fuser assembly having a heat transfer roll

Also Published As

Publication number Publication date
PL349334A1 (en) 2002-07-15
US6573241B1 (en) 2003-06-03
CN1329501A (zh) 2002-01-02
CN1186095C (zh) 2005-01-26
HK1040636A1 (en) 2002-06-21
DE59904569D1 (de) 2003-04-17
CZ20012058A3 (cs) 2001-09-12
KR20010089527A (ko) 2001-10-06
JP2002531516A (ja) 2002-09-24
NO328762B1 (no) 2010-05-10
ES2192880T3 (es) 2003-10-16
CZ295769B6 (cs) 2005-11-16
NO20012716D0 (no) 2001-06-01
HUP0104702A3 (en) 2003-09-29
EP1137430A2 (fr) 2001-10-04
JP4700811B2 (ja) 2011-06-15
BR9915800A (pt) 2001-09-25
DE19856897A1 (de) 2000-06-15
EP1137430B1 (fr) 2003-03-12
PT1137430E (pt) 2003-07-31
WO2000033863A2 (fr) 2000-06-15
AU764744B2 (en) 2003-08-28
HUP0104702A2 (hu) 2002-04-29
IL143528A (en) 2008-04-13
PL202908B1 (pl) 2009-08-31
RU2243783C2 (ru) 2005-01-10
KR100859556B1 (ko) 2008-09-22
HK1040636B (zh) 2003-05-30
NO20012716L (no) 2001-06-01
ATE234108T1 (de) 2003-03-15
CA2353469A1 (fr) 2000-06-15
AU3037400A (en) 2000-06-26
WO2000033863A3 (fr) 2000-11-02
DK1137430T3 (da) 2003-06-16

Similar Documents

Publication Publication Date Title
IL143528A0 (en) Therapeutic agents containing botulinum toxin for the suppression of snoring noises
MXPA02002895A (es) Tratamiento topico de infecciones por estreptococcus.
MX9706095A (es) Enzima multifuncional.
PL319833A1 (en) Compounds and composition for carrying active media
BG100974A (en) Vaccines against papillomavirus
EP1820862A3 (fr) Mise à l'échelle de polarisation de couple d'un côté sur l'autre afin d'améliorer la dérive dans une transmission à quatre roues motrices programmable
ATE552891T1 (de) Kombination von sauren-proteaseenzymen und sauren pufferlösungen sowie deren verwendung
AU9125798A (en) Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
CA2191754A1 (fr) Modification de toxines de clostridium utilisees comme proteines de transport
AU1916995A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity
RU2001116080A (ru) Терапевтический агент для подавления шумов храпа
WO1998001158A3 (fr) Conjugues hemoglobine-amidon hydroxyethyle comme agents de transport d'oxygene
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
AU1436699A (en) The use of polyols in combating yeast infection and polyol preparations for saiduse
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU5956398A (en) Remedies for lymphocytic tumors
CA2253287A1 (fr) Procede pour produire un polypeptide recombine comprenant l'addition d'un inhibiteur de proteases metal-dependantes ou de chymotrypsines au milieu de culture cellulaire
WO2002026245A3 (fr) Methodes de traitement de reactions inflammatoires et immunitaires et compositions associees
WO1996030042A3 (fr) Procedes pour le traitement des inflammations et compositions prevues a cet effet
AU1041397A (en) Antigenic protein originating in malassezia
US5798392C1 (en) Sulfonyl fluorides for the treatment of alzheimer's disease
MXPA05003616A (es) Composiciones que comprenden anfotericina b altamente purificada.
GB2306885B (en) Supersaturated Pharmaceutical Compositions
WO2000042987A3 (fr) Produits de recombinaison vesiculaires cibles utilises pour la protection des cellules et le traitement d'infections provoquees par $i(helicobacter pylori)
IE840977L (en) Pharmaceutical preparations

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed